Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

Clinical Response ◽

Controlled Trial ◽

Severe Psoriasis ◽

Extension Study ◽

Open Label ◽

Double Blind ◽

Randomized Controlled ◽

Open Label Extension ◽

Adalimumab Treatment

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2006.05.027 ◽

2006 ◽

Vol 55 (4) ◽

pp. 598-606 ◽

Cited By ~ 322

Author(s):

Kenneth B. Gordon ◽

Richard G. Langley ◽

Craig Leonardi ◽

Darryl Toth ◽

M. Alan Menter ◽

...

Keyword(s):

Clinical Response ◽

Controlled Trial ◽

Severe Psoriasis ◽

Extension Study ◽

Open Label ◽

Double Blind ◽

Randomized Controlled ◽

Open Label Extension ◽

Adalimumab Treatment

103. Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study

Rheumatology ◽

10.1093/rheumatology/keu101.024 ◽

2014 ◽

Vol 53 (suppl_1) ◽

pp. i96-i96 ◽

Cited By ~ 1

Author(s):

Edward Keystone ◽

Robert Landewé ◽

Ronald van Vollenhoven ◽

Bernard Combe ◽

Vibeke Strand ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Controlled Trial ◽

Certolizumab Pegol ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Randomized Controlled ◽

Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients with Dementia with Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial

American Journal of Geriatric Psychiatry ◽

10.1016/j.jagp.2021.07.002 ◽

2021 ◽

Author(s):

Toshinari Odawara ◽

Kazuko Hasegawa ◽

Ritsuko Kajiwara ◽

Hisao Takeuchi ◽

Masaaki Tagawa ◽

...

Keyword(s):

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

25853 Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: Results of a phase 2 randomized controlled trial with an open-label extension phase

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.313 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB72

Author(s):

Elke Weisshaar ◽

Jacek C. Szepietowski ◽

Thomas R. Sciascia ◽

Gil Yosipovitch ◽

Sonja Ständer

Keyword(s):

Extended Release ◽

Controlled Trial ◽

Extension Phase ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Prurigo Nodularis ◽

Randomized Controlled ◽

Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2016.11.002 ◽

2017 ◽

Vol 11 ◽

pp. 25-31 ◽

Cited By ~ 9

Author(s):

Takahiko Saida ◽

Jun-ichi Kira ◽

Shuji Kishida ◽

Takashi Yamamura ◽

Yukiko Sudo ◽

...

Keyword(s):

Multiple Sclerosis ◽

Pharmacokinetic Study ◽

Controlled Trial ◽

Open Label ◽

Double Blind ◽

Randomized Controlled ◽

Multiple Sclerosis Patients

Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open Open-Label Extension Phase

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.29 ◽

2021 ◽

Vol 5 (1) ◽

pp. s29

Author(s):

Elke Weisshaar ◽

Thomas Sciascia ◽

Sonja Stander

Keyword(s):

Extended Release ◽

Controlled Trial ◽

Extension Phase ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Prurigo Nodularis ◽

Randomized Controlled ◽

Abstract not available.

Faculty Opinions recommendation of Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736001226.793562367 ◽

2019 ◽

Author(s):

Susanne Schneider

Keyword(s):

Controlled Trial ◽

Extension Study ◽

Open Label ◽

Double Blind ◽

Pantothenate Kinase ◽

Safety And Efficacy ◽

Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5‐Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open‐Label Extension of a Randomized Controlled Trial

Journal of Bone and Mineral Research ◽

10.1002/jbmr.4453 ◽

2021 ◽

Author(s):

Andrew Grey ◽

Mark J Bolland ◽

Anne Horne ◽

Borislav Mihov ◽

Greg Gamble ◽

...

Keyword(s):

Bone Mineral Density ◽

Bone Turnover ◽

Older Women ◽

Bone Mineral ◽

Controlled Trial ◽

Mineral Density ◽

Open Label ◽

Randomized Controlled ◽

Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study

Pediatric Rheumatology ◽

10.1186/s12969-016-0106-4 ◽

2016 ◽

Vol 14 (1) ◽

Cited By ~ 19

Author(s):

Lesley M. Arnold ◽

◽

Kenneth N. Schikler ◽

Lucinda Bateman ◽

Tahira Khan ◽

...

Keyword(s):

Controlled Trial ◽

Extension Study ◽

Open Label ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-017-1964-x ◽

2017 ◽

Vol 18 (1) ◽

Cited By ~ 19

Author(s):

Sarah Ballou ◽

Ted J. Kaptchuk ◽

William Hirsch ◽

Judy Nee ◽

Johanna Iturrino ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Study Protocol ◽

Controlled Trial ◽

Placebo Treatment ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Controlled ◽

Irritable Bowel